PT2364983E - Novo derivado tricíclico ou seus sais farmaceuticamente aceitáveis, seu método de preparação, e composição farmacêutica que o contém - Google Patents

Novo derivado tricíclico ou seus sais farmaceuticamente aceitáveis, seu método de preparação, e composição farmacêutica que o contém Download PDF

Info

Publication number
PT2364983E
PT2364983E PT98262702T PT09826270T PT2364983E PT 2364983 E PT2364983 E PT 2364983E PT 98262702 T PT98262702 T PT 98262702T PT 09826270 T PT09826270 T PT 09826270T PT 2364983 E PT2364983 E PT 2364983E
Authority
PT
Portugal
Prior art keywords
preparation
pharmaceutically acceptable
pharmaceutical composition
acceptable salts
composition containing
Prior art date
Application number
PT98262702T
Other languages
English (en)
Inventor
Antonio Infante Da Camara Trigueiros De Aragao
Kim Myung-Hwa
Kim Seung-Hyun
Ku Sae-Kwang
Park Chun-Ho
Chun Kwang-Woo
Ye In-Hae
Choi Jong-Hee
Ryu Dong-Kyu
Park Ji-Seon
Lee Han-Chang
Choi Ji-So
Kim Young-Chul
Original Assignee
Jeil Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeil Pharmaceutical Co Ltd filed Critical Jeil Pharmaceutical Co Ltd
Publication of PT2364983E publication Critical patent/PT2364983E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT98262702T 2008-11-11 2009-11-11 Novo derivado tricíclico ou seus sais farmaceuticamente aceitáveis, seu método de preparação, e composição farmacêutica que o contém PT2364983E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20080111808 2008-11-11

Publications (1)

Publication Number Publication Date
PT2364983E true PT2364983E (pt) 2014-01-07

Family

ID=42170514

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98262702T PT2364983E (pt) 2008-11-11 2009-11-11 Novo derivado tricíclico ou seus sais farmaceuticamente aceitáveis, seu método de preparação, e composição farmacêutica que o contém

Country Status (16)

Country Link
US (1) US8815891B2 (pt)
EP (1) EP2364983B1 (pt)
JP (1) JP5403709B2 (pt)
KR (1) KR100968175B1 (pt)
CN (1) CN102245612B (pt)
AU (1) AU2009314760B2 (pt)
BR (1) BRPI0915273B1 (pt)
CA (1) CA2743257C (pt)
DK (1) DK2364983T3 (pt)
ES (1) ES2443127T3 (pt)
HK (1) HK1164292A1 (pt)
MX (1) MX2011004957A (pt)
PL (1) PL2364983T3 (pt)
PT (1) PT2364983E (pt)
RU (1) RU2470934C1 (pt)
WO (1) WO2010056038A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101827444B1 (ko) * 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
WO2015089842A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Novel tricyclic calcium sensing receptor antagonists for the treatment of osteoporosis
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
MA42032A (fr) 2015-02-02 2018-03-14 Forma Therapeutics Inc Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
US10464919B2 (en) * 2015-06-09 2019-11-05 Je Il Pharmaceutical Co., Ltd. Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
KR101775356B1 (ko) 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
RU2602503C1 (ru) * 2015-09-23 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА) Трициклические соединения, обладающие противобактериальной активностью, способ их получения и содержащее их фармацевтическое средство
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
KR20180062804A (ko) * 2016-12-01 2018-06-11 사회복지법인 삼성생명공익재단 트리시클릭 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 허혈성 급성 신손상 예방 또는 치료용 약학적 조성물
WO2018119208A1 (en) * 2016-12-22 2018-06-28 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
WO2018226998A1 (en) 2017-06-09 2018-12-13 Global Blood Therapeutics, Inc. Azaindole compounds as histone methyltransferase inhibitors
IL296734A (en) * 2018-04-13 2022-11-01 The Institute Of Cancer Res Royal Cancer Hospital bcl6 inhibitors
EP3860996A4 (en) 2018-10-02 2022-08-31 Northwestern University BETA-CARBOLINES AS POSITIVE ALLOSTERIC MODULATORS OF HUMAN SEROTONIN RECEPTOR 2C (5-HT2C)
WO2020155141A1 (zh) * 2019-02-02 2020-08-06 中国科学院上海有机化学研究所 治疗神经退行性疾病或rna结合蛋白发生异常导致的疾病的药物组合物及其应用
KR20210014024A (ko) 2019-07-29 2021-02-08 제일약품주식회사 트리사이클릭 유도체를 이용한 뇌졸중의 치료 방법
JP2022551373A (ja) * 2019-07-29 2022-12-09 ジェイル ファーマシューティカル カンパニー リミテッド 三環式誘導体を用いた脳卒中の治療方法
KR20220149268A (ko) * 2021-04-30 2022-11-08 주식회사 온코크로스 트리사이클로 유도체 화합물을 포함하는 대사질환 예방 또는 치료용 조성물
CN115554303B (zh) * 2021-09-18 2024-07-09 上海科技大学 一种三环类化合物、其制备方法及其应用
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391554A (en) 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
JP2000239273A (ja) * 1999-02-16 2000-09-05 Nippon Kayaku Co Ltd ４−アミノ−５，６，７，８−テトラヒドロ〔１，６〕ナフチリジン誘導体の新規製造法
AR029185A1 (es) * 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
UA82205C2 (en) * 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
DE102004028973A1 (de) * 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
EP1989204B1 (en) * 2006-02-15 2014-05-21 AbbVie Inc. Pyrazoloquinolones are potent parp inhibitors
JP5399905B2 (ja) 2006-09-01 2014-01-29 センワ バイオサイエンシズ インコーポレイテッド セリン−トレオニンタンパク質キナーゼおよびｐａｒｐ調節因子
KR101179753B1 (ko) * 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물

Also Published As

Publication number Publication date
CN102245612B (zh) 2014-11-05
RU2470934C1 (ru) 2012-12-27
PL2364983T3 (pl) 2014-04-30
JP2012508273A (ja) 2012-04-05
AU2009314760A1 (en) 2011-06-30
WO2010056038A3 (ko) 2010-09-16
ES2443127T3 (es) 2014-02-17
HK1164292A1 (en) 2012-09-21
BRPI0915273B1 (pt) 2021-08-03
CN102245612A (zh) 2011-11-16
JP5403709B2 (ja) 2014-01-29
CA2743257A1 (en) 2010-05-20
DK2364983T3 (da) 2013-12-09
US8815891B2 (en) 2014-08-26
EP2364983A4 (en) 2012-05-09
AU2009314760B2 (en) 2011-11-10
WO2010056038A2 (ko) 2010-05-20
MX2011004957A (es) 2011-08-12
CA2743257C (en) 2014-02-11
US20110218193A1 (en) 2011-09-08
KR100968175B1 (ko) 2010-07-07
EP2364983A2 (en) 2011-09-14
EP2364983B1 (en) 2013-10-23
KR20100053468A (ko) 2010-05-20
BRPI0915273A2 (pt) 2015-08-04

Similar Documents

Publication Publication Date Title
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
HK1117164A1 (en) Dicyclic azaalkane derivatives, preparing method and pharmaceutical use thereof
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
IL204521A0 (en) Oxadiazole derivatives, their preparation and pharmaceutical compositions containing them
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
SI2036892T1 (sl) Derivati tetrahidro h benzazepinov postopek za njihovo pripravo in farmacevtski sestavkiki jih vsebujejo
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
IL206062A0 (en) (aza) indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process thereof
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
IL212942A (en) History of Rifamycin, Methods of Preparation, Pharmaceutical Preparations Containing Them and Their Uses
EP2394993A4 (en) A NEW 2,6-SUBSTITUTED 3-NITROPYRIDINE DERIVATIVE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
SI1953161T1 (sl) Novi tricikliäśni derivati, postopek priprave le-teh in farmacevtski sestavki, ki jih vsebujejo
EP2366691A4 (en) NITROPYRIDINYL ETHYLENE HYIN, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, SYNTHESIS METHOD AND APPLICATIONS THEREOF
PL2231598T3 (pl) Nowe pochodne diazeniodiolanów, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
IL205710A (en) History of Spiro [Pipyridine-Benzopyran] Pharmaceuticals Containing Them, Methods of Preparing and Using Their @
EP2284158A4 (en) QUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF
EP2212325A4 (en) 2-ARYLMETHYLAZETIDINCARBAPENEM-3-CARBOXYLENE DERTERIVATE OR SALT, METHOD FOR THE PRODUCTION THEREOF AND THEREOF COMPRISING PHARMACEUTICAL COMPOSITION
IL210377A (en) History of Naphthyridone, their preparation and their pharmaceutical preparations
EP2035406A4 (en) NEW SUBSTITUTED 1H-CHINAZOLIN-2,4-DION DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
ZA200902414B (en) Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP2402333A4 (en) 1,4-BENZOTHIAZEPINE 1-OXIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION USING THE SAME
EP2241571A4 (en) STABLE 6-METHOXY-2 ', 3'-DIDEOXYGUANOSINE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
IL213588A0 (en) Naphthyridine derivatives, their preparation and pharmaceutical compositions containing them